Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ChemDiv Heads Three-Way Development Agreement for Neurodegenerative Diseases | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ChemDiv Heads Three-Way Development Agreement for Neurodegenerative Diseases

Research will focus on Sigma1 dysfunction associated with early onset diseases, such as ALS and Alzheimer's

By: Betsy Louda

, Contract Pharma

ChemDiv Inc., a fully integrated CRO, has entered into a three-way co-development agreement with Context Therapeutics and Torrey Pines Investment to advance research and development in the area of Sigma1 dysfunction associated with early onset neurodegenerative diseases. Under the agreement, ChemDiv grants Context access to its integrated discovery platform, while Torrey Pines will invest in Context and provide network resources to support pre-commercial R&D.

 

This collaboration will allow ChemDiv to capitalize on its resources and experience in drug discovery to help Context expand its pipeline of treatments against Sigma1 mutations that are associated with severe early onset neurodegenerative diseases, such as ALS and Alzheimer’s.

 

“Sigma1 provides a very exciting new R&D target that could offer an alternative to those patients whose needs cannot be met with existing treatments,” said Martin Lehr, co-founder and chief executive officer at Context Therapeutics. “We are looking forward to the fruits of this collaboration, and hope that our collective efforts will streamline the development of a potent cure for Sigma1 associated neurodegenerative diseases around the globe.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters